Disarming the silent threat of ovarian cancer

2026-07-22

Ovarian cancer (OC) is the most lethal of female cancers, often termed a “silent killer”. DISARM’s overall approach to tackle the significant gaps in hereditary OC management lies in tackling both key elements of risk assessment and early detection. The project will investigate multifactorial risk assessment versus standard practices in 4 EU Member States (MS) (Lithuania, Portugal, Czech Republic, and Greece), and will upscale and validate a set of easy-to-use, highly accurate and affordable technologies in five countries (UK, Lithuania, Portugal, Czech Republic, and Greece). Several intelligent digital assets will optimally support and enhance our clinical studies, while a range of multifaceted activities will ensure the future uptake and adoption of DISARM solutions. The project aligns with the Innovation Action character of this topic by focusing on both mature technologies that can be upscaled in routine healthcare and on emerging technologies that have already shown a potential to justify larger scale validation activities. Our ultimate ambition is to holistically investigate the preconditions and set the stage for rolling out proven solutions in routine OC risk assessment, and in parallel to create further evidence for the introduction of novel promising elements in early detection programmes. DISARM gathers 26 partners from 12 countries (10 EU MS, the UK and Canada), thereby exhibiting a significant geographic coverage, strengthening European and international collaboration and ensuring widespread diffusion of the project results. This action is part of the Cancer Mission cluster of projects on ‘Prevention and Early Detection (early detection heritable cancers)

Greece

2025-10-01